Analystreport

Gemphire Therapeutics Inc (NASDAQ: GEMP) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.00 price target on the stock.

GEMPHIRE THERAPEUTICS INC COMMON  (GEMP) 
Last gemphire therapeutics inc common earnings: 5/9 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.gemphire.com